---
schema_version: "secwatch.filing_event.v1"
accession: "0001384101-22-000121"
form_type: "8-K"
ticker: "VCYT"
cik: "0001384101"
company_name: "VERACYTE, INC."
filed_at: "2022-08-11T23:59:59+00:00"
generated_at: "2026-06-24T00:43:11.051194+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Veracyte appoints Eliav Barr, M.D. to board of directors, effective August 9, 2022

## Summary
- Dr. Barr appointed as Class III director with term expiring at 2025 annual meeting.
- Also appointed to the Regulatory and Compliance Committee of the board.
- Receives annual cash retainer of $40,000 plus $5,000 for committee service.
- Initial restricted stock unit grant valued at $500,000, vesting over three years.
- Enters standard indemnification agreement for non-executive directors.

## SEC filing metadata
- accession: 0001384101-22-000121
- form_type: 8-K
- ticker: VCYT
- cik: 0001384101
- company_name: VERACYTE, INC.
- filed_at: 2022-08-11T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1384101/000138410122000121/0001384101-22-000121-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1384101/000138410122000121/vcyt-20220809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001384101-22-000121
- JSON: https://secwatch.observer/filing/0001384101-22-000121.json
- Plain text: https://secwatch.observer/filing/0001384101-22-000121.txt

## Key facts
- Executive change
  Eliav Barr, M.D. was appointed as Director at VERACYTE, INC..
  - Action: appointed
  - Role: Director
  source text: the Board appointed Eliav Barr, M.D., to serve as a director of the Company, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1384101/000138410122000121/0001384101-22-000121-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.